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L-Arginine supplementation inhibits the
growth of breast cancer by enhancing
innate and adaptive immune responses
mediated by suppression of MDSCs in vivo
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Abstract
Background: L-Arg is involved in many biological activities, including the activation of T cells. In breast cancer
patients, L-Arg is depleted by nitric oxide synthase 2 (NOS2) and arginase 1 (ARG-1) produced by myeloid-derived
suppressor cells (MDSCs). Our aim was to test whether L-Arg supplementation could enhance antitumor immune
response and improve survivorship in a rodent model of mammary tumor.
Methods: Tumor volumes in control and L-Arg treated 4 T1 tumor bearing (TB) BALB/c mice were measured and
survival rates were recorded. The percentages of MDSCs, dendritic cells (DCs), regulatory T cells (Tregs),
macrophages, CD4+ T cells, and CD8+ T cells were examined by flow cytometry. Additionally, levels of IL-10, TNF-α,
and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA) and nitric oxide (NO) levels were
measured by the Griess reaction. IFN-γ, T-bet, Granzyme B, ARG-1 and iNOS mRNA levels were examined by
real-time RT-PCR.
Results: L-Arg treatment inhibited tumor growth and prolonged the survival time of 4 T1 TB mice. The frequency
of MDSCs was significantly suppressed in L-Arg treated TB mice. In contrast, the numbers and function of
macrophages, CD4+ T cells, and CD8+ T cells were significantly enhanced. The IFN-γ, TNF-α, NO levels in
splenocytes supernatant, as well as iNOS, IFN-γ, Granzyme B mRNA levels in splenocytes and tumor blocks were
significantly increased. The ARG-1 mRNA level in tumor blocks, the frequency of Tregs, and IL-10 level were not
affected.
Conclusion: L-Arg supplementation significantly inhibited tumor growth and prolonged the survival time of
4 T1 TB mice, which was associated with the reduction of MDSCs, and enhanced innate and adaptive immune
responses.
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Background
Despite advances in multimodal therapies, breast cancer
remains a significant problem that causes deaths in
women worldwide. Although the incidence and mortal-
ity vary by geographical region, the overall incidence of
breast cancer is increasing [1]. Breast cancer is often as-
sociated with immune suppression in humans and L-
arginine (L-Arg) depletion, an occurrence which can be
effectively modeled in tumor-bearing (TB) mice. There-
fore, it is necessary to identify new therapeutic targets
for the breast cancer, especially for the regulation of im-
mune responses.
L-Arg is an essential amino acid for infants and young
children but a conditionally essential amino acid for
adults. It can be metabolized into nitric oxide (NO) and
L-citrulline by inducible nitric oxide synthase (iNOS) or
into urea and L-ornithine by ARG-1 [2]. NO modulates
different cancer-related events. However, several lines of
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research have indicated that NO may have dual effects
in cancer [3]. L-Arg plays a central role in several bio-
logic systems, including the activation of T cell function
[4]. L-Arg depletion by myeloid-derived suppressor cells
(MDSCs), which produce arginase 1 (ARG-1) and NO
synthase 2 (NOS2), is observed in cancer patients [2, 5–7].
This subset of myelomonocytic cells promotes tumor
growth and metastasis, which are highly efficient at sup-
pressing activated T cells, leading to the impairment of
general and tumor-specific adaptive immune responses [2,
8]. Activated T cells cultured in a medium without L-Arg,
or cocultured with ARG-1 producing MDSCs isolated
from tumors, proliferate at a decreased rate, express lower
levels of the T cell receptor CD3 chain, and produce re-
duced levels of cytokines [6, 9, 10]. Such impaired T cell
functions can be reversed by the enteral or parenteral sup-
plementation of L-Arg [11].
Considering that (1) L-Arg level is decreased in tumor
bearing patients and mice [12], (2) anti-tumor T cell im-
munity is usually suppressed, whereas MDSCs which
mediate tumor escape are always enhanced in the tumor
bearers, and (3) L-Arg depletion by MDSCs leads to the
depression of T cells [7, 13], we hypothesized that L-Arg
supplementation would inhibit tumor growth and im-
prove survival. Murine models have been established to
study breast cancer focusing on the specific clinical
questions. In order to test this hypothesis, we supple-
mented the breast cancer-bearing BALB/c mice with L-
Arg and monitored the host’s anti-tumor immune re-
sponses. Results showed that supplementation with L-
Arg prolonged survival time of the host and inhibited
tumor growth. This effect is associated with enhanced
innate and adaptive immune responses. The results sug-
gest that L-Arg supplementation may be a viable pre-
ventative and/or adjunctive treatment for the inhibition
of breast cancer development.
Methods
Cell line and tumor implantation
The 4 T1 mouse mammary carcinoma cell line lacks the
expression of estrogen receptor (ER) and metastasizes to
other organs in a way similar to what is observed in natur-
ally occurring breast cancer in humans [14], thus we se-
lected 4 T1 mouse mammary carcinoma cell line to
establish the breast cancer model. 4 T1 cell line was ob-
tained from the Cell Bank of the Chinese Academy of Sci-
ences (Shanghai, China). All animal experimental protocols
were approved by the Animal Care and Use Committee of
China Medical University. Cells were cultured in RPMI
1640 medium supplemented with 10 % fetal bovine serum
(FBS) and 1 % penicillin-streptomycin, at 37 °C and 5 %
CO2 in a 95 % humidified incubator. L-Arg was purchased
from Sigma-Aldrich (St. Louis, MO, USA) and diluted to
150 mg/ml with phosphate-buffered saline (PBS), pH 7.0.
Female, 6–8-week-old BABL/c mice were purchased from
Academia Sinica Shanghai Experimental Animal Center
(Shanghai, China). Mice were housed under controlled light
and temperature conditions and randomly assigned to ex-
perimental and control groups of ten mice each. 4 T1
mouse mammary carcinoma cells (1 × 105) were injected
subcutaneously into the shaved flanks of mice. L-Arg treat-
ment was then initiated on day 7 post-inoculation when the
diameter of the tumor was palpable. For the dose selection
of L-Arg used in the current study, we examined three dif-
ferent doses L-Arg (2.5 g/kg, 1.5 g/kg and 0.5 g/kg) supple-
mentation on the tumor volume based on published
literature [15, 16], and then 1.5 g/kg L-Arg was chosen to
perform the following studies. Mice in the experimental
group were treated for 20 consecutive days via oral admin-
istration of L-Arg (1.5 g/kg), whereas the control group re-
ceived equal amounts of PBS once a day. To explore the
role of NO, some mice were supplied with water with 1 %
aminoguanidine (AG), an NOS inhibitor. Tumor growth
was monitored every three days by measuring the tumor
length (L) and width (W) using calipers and calculating the
tumor size according to the following formula: Tumor vol-
ume (mm3) =1⁄2 × long diameter × short diameter squared.
At the end of the treatment (day 28 post inoculation), three
animals of each group were euthanized with ether. Tumor
mass, lymph nodes, and spleens were removed for further
analysis.
Flow cytometry
Spleens and lymph nodes from 4 T1 TB BALB/c mice were
dissected and homogenized to produce a single cell suspen-
sion. After red blood cells were lysed, the cells were washed
with PBS (300 × g for 7 min) and adjusted to 1 × 107/ml
with RPMI-1640. Dendritic cells (DCs) were stained with
FITC-anti-CD11c (clone HL3, BD Biosciences), PE-anti-
CD11b (clone M1/70, BD Biosciences), PerCP-anti-
CD45R⁄ B220 (clone RA3-6B2, BD Biosciences) and APC-
MHC II (clone M5/114.15.2, eBioscience). To assess regula-
tory T cells (Tregs), FITC-anti-CD4 (clone H129.19, BD
Biosciences) and PE-anti-CD25 antibodies (clone PC61, BD
Biosciences) were added to spleen cells, and resuspended in
100 μl of PBS supplemented with 3 % FCS for surface stain-
ing. Then, the cells were fixed and permeabilized, and intra-
cytoplasmic staining was performed using APC-anti-Foxp3
(clone FJK16s, eBioscience) antibody. For assessing CD4+
and CD8+ T cells, single cell suspensions from spleens and
lymph nodes were stained with FITC-anti-CD3e (clone
145-2C11, BD Biosciences), PE-anti-CD4 (clone H129.19,
BD Biosciences) and PerCp-anti-CD8α (clone 53–6.7, BD
Biosciences). For the staining of macrophages and MDSCs,
PerCP cy5.5-anti-F4/80 (clone BM8, ebiosciences), FITC-
anti-CD11b (clone M1/70, BD Biosciences), and APC-anti-
Gr-1 (clone RB6-8C5, BD Biosciences) were added into the
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100 μl single splenocyte suspension and incubated for
30 min at 4 °C.
Intracellular cytokine staining assays were performed
as described elsewhere [17]. Briefly, cells isolated from
spleens were stimulated with PMA (50 ng/ml), ionomy-
cin (1 μg/ml), and brefeldin (Sigma) in order to induce
IFN-γ production. LPS (1 μg/ml) and GolgiPlugô were
used to induce IL-12 production. Following stimulation,
the cells were incubated for 5 h in RPMI 1640 medium
containing 10 % FBS at 37 °C. Cells were collected and
washed twice followed by surface staining as described
above. The cells were then fixed and permeabilized with
Cytofix/Cytoperm (BD Biosciences) according to the
manufacturer's instructions and stained intracellularly
with PE-anti-IFN-γ (clone XMG 1.2, BD Biosciences)
and PE-anti-IL-12p40/70 (clone C15.6, BD Biosciences)
or with corresponding isotope control antibodies for
30 min in permeabilization buffer (BD Biosciences).
After washing twice in permeabilization buffer, the cells
were resuspended in PBS.
For tumor staining and ROS measurement, tumors were
removed from each mouse at the end of treatment and
minced into small pieces and digested with 500 U/ml colla-
genase (type IV, Sigma) for 1 h at 37 °C with agitation. The
resultant cells were passed through nylon mesh to remove
debris, and viable cells were washed with PBS with 2 %
FBS. Intracellular ROS generation was assessed using 2’,7,-
dichlorofluorescein diacetate (DCFH-DA , Sigma). Briefly,
1 × 106 cells were plated on the 6-well plates and incubated
with DCFH-DA (10 mmol/L) for 30 min at 37°C oC and
stained with corresponding antibodies as described above.
After washing twice with PBS, the cells were resuspended
in PBS containing 5 % FCS.
Data were acquired using FACS Calibur (BD Biosci-
ences, San Diego, CA, USA) and analyzed using FlowJo
v7.6.2 (Tree Star Inc., Ashland, OR, USA).
Cytokine assays by ELISA and NO assay by Griess reaction
Splenocytes harvested from each group of mice were
cultured for 48 h followed by collection of the superna-
tants. Levels of IFN-γ, TNF-α and IL-10 were deter-
mined with a corresponding ELISA kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s in-
structions. To determine NO production, concentrations
of NO2
− in cell supernatants were measured by the
Griess reaction [18]. Briefly, 100 μl of the supernatant
was incubated with 100 μl of Griess reagent [equal vol-
umes of 1 % (w/v) sulfanilamide (Wako, Osaka, Japan)
and 0.1 % (w/v) N-1-naphtyl ethylenediamine dihy-
drochloride (Wako) in 2.5 % (w/v) H3PO4] for 10 min at
room temperature, and NO2
− concentration was deter-
mined by measuring the optical density at 550 nm
(A550) in reference to the A550 of standard NaNO2
solution.
RNA isolation and real-time RT-PCR
Total RNA of spleen cells (5 × 106) and Tumor tissue
(nearly 100 mg) was extracted by using Trizol (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s in-
structions and quantified by OD at 260 nm using a UV-
VIS spectrophotometer (PYE-UNICAM, USA). To re-
move genomic DNA contamination, RNA was treated
with DNaseI and reverse-transcribed using a prime-
script reagent kit (Takara Biotechnology, China). cDNA
was synthesized using PrimeScriptTM RT reagent kit
with gDNA Eraser (Takara). Reverse transcription was
performed in a 10 μl reaction mixture containing Prime-
ScriptTM buffer, PrimeScriptTM RT enzyme mix, oligo
dT primer (50 μM), random 6 mers (100 μM) and
500 ng of total RNA. PCR was performed with the
resulting cDNA as a template and specific oligonucleo-
tide primers. Primers used for the sequence-specific
PCR were shown in Table 1. Quantitative PCR was car-
ried out using a SYBR® Premix Ex Taq™ reagent kit
(Takara) on ABI 7500 (ABI, USA). After denaturation at
95 °C for 30 s, 40 cycles of PCR (95 °C for 5 s and 60 °C
for 30 s) were performed. Amplification of the β-actin
sequence served as an internal control. Each experiment
was performed three times independently. The average
cycle threshold (CT) of the duplicate measurements was
calculated. After verifying that amplification efficiencies
of the target genes and β-actin were approximately
equal, the 2-ΔΔCT method was used to quantify the rela-
tive gene expression in the PBS group and experiment
groups.
Statistics analysis
Survival analysis was tested by the Kaplan–Meyer
method. Results were expressed as the mean value ± SD
and interpreted by Student’s t-test. Differences were con-
sidered statistically significant when P < 0.05.
Table 1 Primer sequences for RT-PCR
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Results
L-Arg supplementation slows the growth of 4 T1 breast
carcinoma cells and prolongs survival
To determine whether L-Arg supplementation in
4 T1 TB mice could improve the survival of mice upon
tumor development, 4 T1 TB mice were orally adminis-
tered with L-Arg for 20 consecutive days beginning
when the tumor was palpable. We found that L-Arg sup-
plementation could inhibit tumor growth in 4 T1 TB
mice, and tumor volume in the L-Arg supplementation
group was significantly smaller than the control group
from day 28 on (P < 0.05, t-test) (Fig. 1a). Similarly, the
tumor size and weight from the L-Arg treatment group
was significantly reduced (P < 0.05, t-test) compared with
that of the control group (Fig. 1b and c). In addition,
there was a significant difference in the survival curve
between L-Arg treatment and control groups (P < 0.01,
Kaplan-Meier analysis). All mice in the PBS group died
between day 32 and 47 post 4 T1 cell inoculation. In
contrast, L-Arg treatment significantly prolonged the
survival of 4 T1 inoculated mice, with death beginning
at 48 days post 4 T1 inoculation (Fig. 1d).
L-Arg suppresses the MDSCs from spleen and tumor
In TB mice, a heterogeneous mixture of myeloid cells
expands at various stages of development. These cells
may not only inhibit anti-tumor immunity but also dir-
ectly stimulate tumorigenesis as well as tumor growth
and expansion. This population efficiently suppresses T
cell immune functions and is characterized primarily by
expression of CD11b and Gr-1 [4]. Here, we compared
the frequencies of MDSCs (CD11b+ Gr-1+) from the
spleens and tumors in both L-Arg and control
groups. As shown in Fig. 2a and b, oral administra-
tion of L-Arg significantly reduced the percentage of
MDSCs from both splenic cells (P < 0.05, t-test) and
tumor cells (P < 0.05, t-test) as well as the number of
MDSCs in the spleen in 4 T1 TB mice. Meanwhile, L-Arg
treatment significantly decreased the ROS levels in
MDSCs in the tumor tissues (P < 0.05, t-test) (Fig. 2c).
These results indicated that L-Arg supplementation may
lead to enhanced anti-tumor immune responses.
L-Arg supplementation promotes Gr-1+CD11b−F4/80+
macrophages but suppresses Gr-1+CD11b+F4/80+
macrophages
To analyze whether L-Arg treatment influenced the fre-
quency and functional state of macrophages, we first com-
pared the percentages of two different populations of
macrophages (CD11b+F4/80+ and CD11b− F4/80+ gated in
Gr-1) in the spleen. As shown in Fig. 3a, L-Arg treated TB
mice produced a lower percentage of Gr-1+CD11b+F4/80+
macrophages (P < 0.05, t-test), but a higher percentage of
Gr-1+CD11b−F4/80+ macrophages (P < 0.05, t-test) com-
pared to control mice. Real-time RT-PCR analysis of the
transcript levels of iNOS and ARG-1 showed that L-Arg
treatment significantly elevated the expression of
iNOS (P < 0.05, t-test), compared with PBS and L-Arg
+ AG groups in tumor (Fig. 3b). ARG-1 mRNA level
was also elevated by L-Arg or L-Arg + AG treatment,
but no statistically significance was detected between
PBS and experiment groups (Fig. 3b). L-Arg treatment





































































Fig. 1 L-Arg treatment improved the survival of mice and inhibited the growth of 4 T1 mammary carcinoma in mice. (a) Growth curve of 4 T1
tumors between L-Arg and PBS groups. Tumor blocks (b) and weights (c) removed from the two groups at the end of treatment were compared.
The survival (d) of 4 T1 TB mice (n = 7) was checked every day. * P < 0.05 and ** P < 0.01 compared to PBS group
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stimulated the macrophages to produce a significantly
higher level of NO (P < 0.05, t-test) in the supernatant
of cultured splenic cells than that in PBS and L-Arg
+ AG groups (Fig. 3c). No statistically significance be-
tween PBS and L-Arg + AG groups was detected in
this experiment (Fig. 3b and c). These results demon-
strated that L-Arg could decrease the numbers of im-
mature macrophages, leading to elevated levels of
iNOS mRNA and NO in 4 T1 TB mice.
L-Arg promotes the differentiation and activation the of
DCs in 4 T1 TB mice
Our next step was to determine whether the observed
reduction in tumor mass was associated with enhanced
immune responses elicited by L-Arg through the sup-
pression of MDSCs. We first examined the L-Arg medi-
ated regulation of the subsets and maturation of DCs
late in breast cancer development. As shown in Fig. 4,
there were higher percentages and numbers of myeloid
DCs (mDCs, CD11c+ CD11b+) (P < 0.05, t-test) and plas-
matocytoid DCs (pDCs, CD11c+ B220+) (P < 0.05, t-test)
in the L-Arg supplement group than the control group.
In addition, elevated maturation of CD11c+ DCs was ob-
served, evidenced by the increased expression of MHC
II (CD11c+ MHC II+) following L-Arg treatment (P <
0.05, t-test). Finally, increased frequency and number of
CD11c+ DCs secreting IL-12 (CD11c+ IL-12+) at the end
of L-Arg treatment was observed (P < 0.05, t-test). These
results indicated that L-Arg treatment could initiate the
expansion and activation of DCs.
L-Arg promotes Th1 immune responses leading to
inhibition of cancer development
In order to determine whether L-Arg treatment pro-
moted Th1 immune response, the percentages of CD4+
and CD8+ T cells from lymph nodes and spleen were
measured (Fig. 5a and b). The results showed that L-Arg
increased the percentage of CD8+ cytotoxic T lympho-
cytes (CTLs) (P < 0.05, t-test) (Fig. 5f and g). We also
found that L-Arg had no effect on the number of IFN-γ
producing CD4+ T cells (CD4+ IFN-γ+) in the spleens of
TB mice (Fig. 5d). However, the level of Th1 transcrip-
tional factor T-bet significantly increased upon L-Arg
treatment (Fig. 5c). Furthermore, as shown in Fig. 5e,
TNF-α and IFN-γ levels in splenocyte supernatants were
significantly increased in L-Arg treated TB mice com-
pared to control mice (P < 0.05, t-test). Finally, we deter-
































































Fig. 2 L-Arg suppressed MDSCs from spleens and tumors of 4 T1 TB mice. The frequencies and absolute numbers of MDSCs in the spleens and
tumors (a and b) were assayed by FACS. Mean fluorescence intensity (MFI) (c) of ROS in MDSC obtained from tumor in 4 T1 TB mice. * P < 0.05
compared to PBS group
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Granzyme B and IFN-γ in the tumor (Fig. 5h), and re-
sults showed L-Arg treatment significantly enhanced fre-
quency and CTLs, and mRNA level of Granzyme B (a
10-fold increase compared with PBS) and IFN-γ (4-fold
compared with PBS) significantly elevated. These results
indicated that L-Arg supplementation promoted the de-
velopment of adaptive immune response in TB mice.
L-Arg has no effect on the Tregs in 4 T1 TB mice
As an important group of immune-suppressive cells,
Tregs are considered to play a key role in the escape of
tumor cells from host protective immune responses [19].
We next assessed whether L-Arg treatment could affect
the number of Tregs (CD4+ CD25+ Foxp3+) in TB mice.
The results from FACS analysis showed that L-Arg treat-
ment had no effect on Tregs in TB mice (Fig. 6a and b).
In addition, IL-10 levels produced by splenic cells were
similar between the L-Arg and PBS groups, a result that
was consistent with unaltered Treg levels (Fig. 6c). These
data revealed that supplementation with L-Arg treat-
ment had no obvious effect on Tregs in 4 T1 TB mice.
Discussion
Mouse models are important tools to investigate the im-
mune response and immunotherapeutic outcomes in can-
cer. In some experimental tumor models, L-Arg increases
the latency period and survival rate, reduces tumor size
and incidence, shortens the time of tumor regression, and
inhibits tumor growth compared with other dietary inter-
ference or no dietary supplementation [20–22]. Dietary
supplementation with L-Arg in patients with breast cancer
significantly enhances host defenses [23, 24], and therefore
may have a beneficial therapeutic role. In a related study,
supplement of L-Arg significantly reduced the incidence
of colorectal cancer due to a nonspecific stimulation of
the host immune system [25]. In the present study, we
supplemented 4 T1 TB mice with L-Arg and monitored
anti-tumor immune responses. The results revealed that
L-Arg prolonged survival time by inhibiting tumor
growth. This was associated with the suppression of
MDSCs and enhanced innate and adaptive immune re-
sponses. This suggests that L-Arg might be used as an ad-
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Fig. 3 L-Arg affected two different populations of macrophages in the spleens of 4 T1 TB mice. Two populations of macrophages (CD11b+F4/80+ and
CD11b−F4/80+ gated in Gr-1) were shown (a). Total RNA was purified from tumor block and ARG-1 and iNOS mRNA were quantified by real-time
RT-PCR (b). NO levels from the supernatant of cultured splenic cells were evaluated by the Griess reaction (c). * P < 0.05 and ** P < 0.01 compared to
PBS group. ## P < 0.01 compared to L-Arg + AG group
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MDSCs, typically positive for both CD11b and Gr1 in
mice, are a population of immature myeloid cells defined
by their suppressive actions on T cells, DCs, and natural
killer cells. MDSCs can suppress T cell immune function
via constitutive production of ARG-1, an enzyme re-
sponsible for significant L-Arg depletion [10, 26]. In
addition to inhibiting T cells activation, MDSCs also im-
pact anti-tumor immunity by perturbing innate immun-
ity through their interactions with macrophages, NK
cells, and NK T cells [27, 28]. Both MDSCs and T cells
require L-Arg for protein synthesis. MDSCs produce
high levels of intracellular arginase requiring them to
import excess arginine through their CAT-2B trans-
porter [29, 30]. As a result, they deplete L-Arg and limit
L-Arg availability to T cells in the tumor microenviron-
ment. Without L-Arg, naïve T cells in TB individuals
cannot efficiently traffic to lymph nodes or tumor sites.
MDSCs were found to infiltrate into tumors and pro-
mote tumor angiogenesis by producing high levels of
MMP9 and by directly incorporating into tumor endo-
thelium [31]. Hence, as a therapeutic target, down-
regulation of MDSCs frequencies and/or abrogation of
their immunosuppressive functions delay the tumor
growth and prolong the survival both in animal models
and in cancer patients [32–34]. Regulation of MDSCs in-
cludes the prevention of generation from bone marrow
precursor cells and the stimulation of MDSCs
differentiation towards mature DCs and macrophages.
Therapeutic interventions targeting MDSCs may not
only enhance the host immune system but also inhibit
tumor invasion and metastasis [35]. In the present study,
the frequencies of MDSCs were significantly suppressed
in the 4 T1 TB mice after supplementation with L-Arg,
and consistently, anti-tumor immunity was enhanced.
Our results showed that L-Arg supplementation en-
hanced the anti-tumor immunity by suppressing the
number of MDSCs in 4 T1 TB mice. This is in agree-
ment with the recent report that L-Arg depletion
blunted antitumor T-cell responses by inducing MDSCs
[7]. Although the mechanism remains unclear, such in-
verse correlation between L-Arg and MDSCs may be
mediated by the kinase GCN2, a key mediator of the ef-
fects induced by amino acid starvation [7]. In addition,
several possible factors regulating MDSCs including
VEGF, S100A8/A9, GM-CSF, and G-CSF may be in-
volved in the downregulation of MDSCs by L-Arg sup-
plementation. Dietary L-Arg was reported to decrease
plasma VEGF [36]. More experiments are required to
identify the key molecules to bridge the MDSCs and L-
Arg in the breast cancer model in the future.
Macrophages, which are pivotal regulators in homeo-
static tissue and tumor microenvironments, play dual
roles during the progression of cancer. In one role, they
activate and present tumor antigens to T cells, which are
a
b
















































Fig. 4 Effect of L-Arg treatment on DCs in 4 T1 TB mice. The frequencies (a) and absolute numbers (b) of mDCs, pDCs, CD11c+ MHC II+DCs, and
CD11c+ DCs secreting IL-12 were determined in 4 T1 TB mice. Results are representatives of three independent experiments. * P < 0.05
and ** P < 0.01 compared to PBS group
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then activated to kill tumor cells [37]. At the same time,
they release high levels of NO and ROS to kill tumor
cells [38, 39]. On the other hand, as the immune surveil-
lance is not sufficient anymore to prevent the occur-
rence of cancer, tumor-associated macrophages (TAM)
contributes to tumor progression [40, 41]. Many obser-
vations indicate that TAM (Gr-1+ CD11b+ F4/80+) pro-
mote tumor progression and metastasis [42, 43]. In our
study, flow cytometric analysis of splenic F4/80+ macro-
phages revealed that more than 90 % of the Gr-1+ cells
had a CD11b+F4/80+ macrophage phenotype, which also
was considered as a subset of MDSCs [42]. L-Arg treat-
ment significantly decreased this population but elevated
the frequency of CD11b−F4/80+ macrophages. In our
study, L-Arg significantly elevated the mRNA level of
iNOS, but not ARG-1, which was consistent with the
higher level of NO. An earlier study showed that L-Arg
could block the formation and development of colorectal
tumors, and this effect might be related to the increased
serum NO concentration and decreased ornithine de-
carboxylase activity [44]. Our results also indicated that
L-Arg supplementation could significantly elevate the
NO level in 4 T1 TB mice which was consistent with the
increased level of CD11b−F4/80+ macrophages. How-
ever, NO was reported to have both deleterious and
protective effects in the breast cancer [38, 45, 46].
Therefore, we further evaluated the role of NO in
breast cancer by supplementation of an NOS inhibi-
tor, aminoguanidine (AG) into the 4 T1 TB mice with
L-Arg supplementation (L-Arg + AG). The results
showed that L-Arg and L-Arg + AG treatment had a
comparable suppressive effect on tumor tissue weight
(data not shown), which reflects the complexity of
NO in breast cancer. Considering the divergent cell
sources of NO including macrophages [47], T cells
[48], MDSCs [49], tumor cells [50], we speculate that
the distinct sources and different bioavailability levels
of NO may account for the inconsistent roles of NO
in the tumor models. In addition, NO may serve as
one but not the only one (such as IFN-γ, CTL) pro-
tective effector in the tumor bearing mice supple-
mented with L-Arg. Thus the exact role of NO in
breast cancer needs to be explored in the future.
DCs play a pivotal role in bridging innate and adaptive
immune responses. MDSCs decrease DC maturation, as






Fig. 5 L-Arg promoted adaptive immune responses and inhibited cancer development. Flow cytometry analysis of CD4+ T cells, CD8+ T cells, and
CD4+ IFN-γ+ T cells was shown (a, b, d, f and g). Total RNA was purified from spleen cells and T-bet mRNA were quantified by real-time RT-PCR
(c). ELISA was used to determine the levels of TNF-α and IFN-γ (e). Total RNA was purified from tumor tissue and Granzyme B and INF-γ mRNA
were quantified by real-time RT-PCR (h). * P < 0.05 compared to PBS group
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induce IFN-γ production in T cells [51]. In this study,
immature DCs in TB mice were increased compared to
the control group. A corroborating study showed that
dietary supplementation with L-Arg enhanced T cell me-
diated immune function in healthy animals and human
beings [52, 53]. We also found that L-Arg could pro-
mote the differentiation and activation of DCs in the
spleen, which was associated with the initiation of the
anti-tumor immune responses in TB mice. Our data
showed that L-Arg treatment significantly increased the
frequencies of mDCs and pDCs. IL-12 increases the cap-
abilities of professional APCs in the tumor stromal and
activates CD8+ T cells to detect antigen cross-
presentation [54, 55]. In the 4 T1 model, IL-12 stimu-
lates MDSCs to develop into mature myeloid cells.
MDSCs obtained from tumors and spleens of tumor
bearing mice treated with IL-12 up-regulated the surface
markers of macrophages (F4/80 and MHC II) and DCs
(CD80 and CD86) suggesting differentiation into more
mature, less immunosuppressive forms. The spleens ob-
tained from tumor-bearing mice also had up-regulation
of many dendritic cell and macrophage maturation
markers such as CD80, CD86, F4/80 and MHCII [56].
At the same time, high levels of IL-12 synthesized by
mature DCs enhance both innate and acquired immun-
ity [57, 58]. In this experiment, we found expression of
MHC II and secretion of IL-12 by DCs were both sig-
nificantly increased by L-Arg treatment.
L-Arg deprivation induces T cell hyporesponsiveness,
as defined by profound reduction of T cell proliferation
and reduced CD3ζ chain expression [6, 9]. Tumor-
infiltrating CTLs have antitumor activity as judged by
their favorable effect on patients’ survival and could po-
tentially be exploited in the treatment of breast cancer
[59]. However, T cells show anergy as both antigen-
specific CD4+ and CD8+ T cells are tolerant to tumors.
The mechanisms of CD8+ T cell tolerance to tumors in-
clude MDSCs [27] and Tregs [60]. MDSCs are also de-
tected in tumor infiltrates and inhibit effector phase lytic
functions of CD8+ tumor infiltrating lymphocytes [61].
A recent study showed that treatment of TB mice with
5-fluorouracil led to a major depletion of MDSCs in vivo
but increased IFN-γ production by tumor-specific CD8+
T cells infiltrating the tumor and promoted T cell
dependent antitumor responses in vivo [62]. These re-
sults indicated that therapy targeting MDSCs could be
an effective method of cancer treatment. Our results
demonstrated that L-Arg supplementation could reverse
the immunosuppresive effects of MDSCs in 4 T1 TB
mice as CD8+ T cells were significantly elevated within
tumors. Undoubtedly, granzyme B is involved in an im-
portant pathway for CTL/NK cells-induced apoptosis
[63], and L-Arg significantly elevated the mRNA level of
granzyme B in tumor. Though CD4+ T cells producing
IFN-γ was not increased, supplementation of TB

























Fig. 6 L-Arg had no effect on Tregs in 4 T1 TB mice. (a) and (b) We assessed the percentages of CD25+ Foxp3+ T cells gated on CD4 between
the PBS and L-Arg group. (c) The level of IL-10 present in cultured splenic cell supernatants was assessed by ELISA. Results are representative of
three independent experiments
Cao et al. BMC Cancer  (2016) 16:343 Page 9 of 11
T-bet, and also improved IFN-γ production. As a pro-
inflammatory cytokine, IFN-γ induced surface expression
of PD-L1 in breast cancer cells to induce the apoptosis of
cancer cells [64].
In breast cancers, the percentage of Tregs, as assessed
by Foxp3 positivity, increases in parallel with the disease
stage [65, 66], indicating that the presence of Tregs pro-
motes tumor progression through immunosuppression.
IL-10 has been shown to modulate apoptosis and sup-
press angiogenesis during tumor regression [67, 68].
Here, our results showed that the level of Tregs tran-
scription factor Foxp3 was significantly reduced upon L-
Arg treatment.
In summary, L-Arg is an essential amino acid for pro-
moting T cell function. However, the depletion of L-Arg
by MDSCs in breast cancer patients or TB mice greatly
reduces the anti-tumor immune responses. L-Arg sup-
plementation in breast cancer bearing mice significantly
decreased MDSCs as well as the ROS expression levels.
This decrease was associated with enhanced innate and
adaptive immune responses targeting tumors of the
4 T1 TB mice.
Conclusion
Our results suggest that L-Arg supplementation may
represent an effective adjunct therapy of breast cancer
therapy to overcome immunosuppression mediated both
by MDSCs and tumor cells to achieve better therapeutic
effects in cancer patients.
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